NICE Issues Positive Final Appraisal Determination Recommending The Use Of Basileas Toctino
Basilea Pharmaceutica Ltd. (SWISS BSLN) announces that the National Institute for Health and Clinical Excellence (NICE) issued the Final Appraisal Determination (FAD) recommending the use of Toctino® (alitretinoin) within its licensed indication, as a treatment option for adults with severe chronic hand eczema that has not responded to potent topical corticosteroids.
The FAD published today [...]